A modified peptide stimulation method for efficient amplification of cytomegalovirus (CMV)-specific CTLs

Cellular and Molecular Immunology

Volumn 5, Issue 3, 2008, Pages 197-201

  Ruan, Guangping ^a   Ma, Li ^a   Wen, Qian ^a   Luo, Wei ^a   Zhou, Mingqian ^a   Wang, Xiaoning ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

cytomegalovirus; Cytotoxic T lymphocyte; tetramer assay

Indexed keywords

CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; EPITOPE; HLA A2 ANTIGEN; MATRIX PROTEIN; OLIGOPEPTIDE; PHOSPHOPROTEIN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; SYNTHESIS; VIROLOGY;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKOCYTES, MONONUCLEAR; OLIGOPEPTIDES; PHOSPHOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 51049122631     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2008.24     Document Type: Article

References (13)

1. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic transplant recipients. Blood. 1999;93:1781-1782. (Pubitemid 29102509)
2. Krause H, Hebart H, Jahn G, Mueller CA, Einsele H. Screening for CMV-specific T-cell proliferation to identify patients at risk of developing late-onset CMV disease. Bone Marrow Transplant. 1997;19:1111-1116. (Pubitemid 27267735)
3. Zaia JA, Galiez-Hawkins GM, Tegtmeier BR, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis. 1997;176:782-785. (Pubitemid 27360551)
4. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immunoglobulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis. 1992;14:831-835.
5. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science. 1992;257:238-241.
6. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922. (Pubitemid 35332029)
7. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood. 2001;97:994-1000. (Pubitemid 32154284)
8. Ruan GP, Ma L, Meng MJ, et al. Improved preparation of class I HLA tetramers and their use in detecting CMV-specific CTL. J Immunol Methods. 2006;312:148-156. (Pubitemid 43795983)
9. Sharrock CE, Kaminski E, Man S. Limiting dilution analysis of human T cells: a useful clinical tool. Immunol Today. 1990;11:281-286. (Pubitemid 20223324)
10. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
11. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195-216. (Pubitemid 27303130)
12. Sun Q, Pollok KE, Burton RL, et al. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood. 1999;94:3242-3250. (Pubitemid 29512734)
13. Carlsson B, Cheng WS, Totterman TH, Essand M. Ex-vivo stimulation of cytomegalovirus (CMV) specific T-cells using CMV pp65-modified dendritic cells as stimulators. Br J Haematol. 2003;121:428-438. (Pubitemid 36628334)